AzTrials
AzTrials

Swallowing DisordersEph-LNCT06014710

Modelling of Pharyngeal Laryngeal Effectiveness

A study testing Swallowing evaluation in people with Swallowing Disorders, run by University Hospital, Toulouse at 4 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The purpose of this study is to collect the signals of pharyngeal laryngeal activity through five non-invasive sensors (microphone, accelerometer, surface electromyography (EMG), nasal cannula and oximeter) in order to identify indicators of functional efficiency of swallowing, protection of the lower airways and… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Swallowing Disorders
What is being tested?
Swallowing evaluation
Could I receive a placebo?
No, everyone receives an active treatment
How many people
520 participants
Where
4 sitesFrance
Study dates
14 Apr 2023to Oct 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Indication to perform a swallowing test (suspected or proven swallowing disorder or presence of a complication)
  • Able to follow up by phone for 6 months or have a caregiver who can answer for them
  • Affiliated subject or beneficiary of the social security system
  • Consent to participate obtained in writing and signed by the subject or, if applicable, the next of kin/support person
  • No swallowing disorder or discomfort (DHI score<8)
  • Affiliated subject or beneficiary of the social security system
Show all 29Show fewer
  • Signed Consent to Participate
  • Non-inclusion criteria for patients with swallowing disorders :
  • Skin lesion(s) at the neck
  • Tracheotomy or tracheostomy (laryngectomy)
  • Nasogastric probe
  • Iodine allergy
  • Asthma
  • Refusal or any pathology incompatible with passing one of the two reference exams or the sensors used
  • Any serious pathology (severe health or behavioral disorders) where, according to the investigator, this could expose participants to additional risks
  • Legal protection (guardianship, curators, safeguarding of justice)
  • Pregnant and lactating women
  • Non-inclusion criteria for healthy volunteers :
  • Medical history may result in chronic (history of oral-rhino-laryngeal cancer or neurological disease) or temporary (upper respiratory tract infections) swallowing impairment
  • Presence of swallowing disorder or discomfort (Deglutition Handicap Index score superior or equal to 8)
  • Skin lesion(s) at the neck
  • Tracheotomy or tracheostomy (laryngectomy)
  • Nasogastric probe
  • Iodine allergy
  • Asthma
  • Refusal or any pathology incompatible with passing one of the two reference exams or the sensors used
  • Any serious pathology (severe health or behavioral disorders) where, according to the investigator, this could expose participants to additional risks
  • Legal protection (guardianship, curators, safeguarding of justice)
  • Pregnant and lactating women

Who cannot join

None listed.

Trial locations and contacts

4 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Virginie WOISARD, MD contact

33-567771718

woisard.v@chu-toulouse.fr

Gaelle SORIANO contact

soriano.g@chu-toulouse.fr

France4 sites, 4 recruiting
  • University hospital of Bordeaux

    Bordeaux, 33000

    Emmanuelle CUGY, MD

    Emmanuelle CUGY

    Not yet recruiting
  • University hospital of Rouen

    Rouen, 76038

    Eric VERIN, MD

    Eric VERIN

    Not yet recruiting
  • University Hospital of Toulouse

    Toulouse, 31059

    Virginie WOISARD, MD, woisard.v@chu-toulouse.fr

    MD WOISARD, MD

    Recruiting
  • University hospital of Tours

    Tours, 37000

    Sylvain MORINIERE

    Sylvain MORINIERE

    Recruiting

Other trials in France

About this study

Official title: Modelling of Pharyngeal Laryngeal Effectiveness to Assess Swallowing Disorders

The purpose of this study is to collect the signals of pharyngeal laryngeal activity through five non-invasive sensors (microphone, accelerometer, surface electromyography (EMG), nasal cannula and oximeter) in order to identify indicators of functional efficiency of swallowing, protection of the lower airways and phonation.

440 patients (subjects with swallowing disorders), spread over 4 centers and 80 healthy subjects spread over 2 centers will be recruited for the study in an interventional research study involving the prospective, multicentric and longitudinal.

Read more

Pharyngolaryngeal effectiveness will be measured from 6 indicators identified by examinations or reference tests grouped into 3 functions:

  • swallowing: pharyngeal transport capacity (Yale Residue) and Penetration Aspiration Scale (PAS) rated by videofluoroscopy of swallowing (VFS) or flexible endoscopic evaluation of swallowing (FEES);
  • airway protection: cough trigger (citric acid test) and cough power (peak expiratory flow);
  • phonation: vocal efficiency (maximum phonation time) and velar efficiency (nasal scores).

The signals obtained from the 5 sensors will be annotated. Stochastic modelling based on hidden Markov models will be used initially and followed by the implementation of deep neural networks to model indicators. For the complication's prediction algorithm, deep neural networks will also be used to evaluate signal-based methods.

The expected benefits are to obtain automated recognition of pharyngeal-laryngeal effectiveness to diagnose swallowing disorders using objective and quantifiable indicators, non-invasive devices, to assess the severity of these disorders and to identify the risk of complications.

Read the detailed description

The process of swallowing is complex and difficult to assess because of its dynamic nature, the lack of specialists and the technical means necessary for its exploration. Thus, the majority of patients with swallowing disorders do not benefit from any specific instrumental evaluation yet essential to the diagnosis of different types of disorders. The precise analysis of the deficit and its causes makes it possible to guide the choice of adaptation or rehabilitation strategies, with the aim of preventing the risk of complications, mainly nutritional (malnutrition) and respiratory (pneumonia). The development of new, more accessible diagnostic techniques would improve access to care for this population. The purpose of this study is to collect the signals of pharyngeal laryngeal activity through five non-invasive sensors (microphone, accelerometer, surface EMG, nasal cannula and oximeter) in order to identify indicators of functional efficiency of swallowing, protection of the lower airways and phonation. Modelling the mechanisms of pharyngeal-laryngeal efficacy through the use of artificial intelligence would provide an automated assessment of disorders and prognostic risk of complications.

Primary objective: From the signals of 5 non-invasive sensors, model a multidimensional scale of pharyngeal-laryngeal efficiency measuring the 3 main functions of pharyngeal-larynx: swallowing function (evaluated by pharyngeal transport and closure of the larynx) ; airway protection function (evaluated by cough reflex and cough power); phonation function (evaluated by voice and velar efficiency)

Secondary Objectives:

  • Develop a diagnostic model of different physiopathological mechanisms of swallowing
  • Determine an algorithm that can predict the severity of these disorders based on pharyngeal efficacy indicators
  • Determine an algorithm capable of predicting the risk of complications from swallowing disorders, based on modelling pharyngeal effectiveness (primary objective) and clinical data

Study design: An interventional research study involving the prospective, multicentric and longitudinal human person to develop a scale of pharyngeal-laryngeal effectiveness measured from signals from 5 non-invasive sensors. The signals will be collected from each participant using the sensors (microphone, accelerometer, nasal cannula, surface EMG and oximeter). Algorithms will be developed from these signals to predict different indicators of pharyngeal-laryngeal efficiency measured by baseline tests. The study population will include patients with swallowing disorders (to identify pathological signal patterns) and healthy volunteers (to identify non-pathological physiological patterns of swallowing mechanisms).

440 patients (subjects with swallowing disorders), spread over 4 centers and 80 healthy subjects spread over 2 centers will be recruited for the study.

Research procedures

For patients with swallowing disorders:

During a hospital visit as part of their care pathway, patients with the criteria will be offered to participate in the research protocol. The subjects who have given their written consent will then carry out their assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. For research purposes, the subjects will also perform a cough and phonation test and questionnaires. Other data used are collected as part of routine care.

At the end of the assessment, the patient will receive management advice based on the reference exams and his medical record.

Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications, The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.

For healthy volunteers:

Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)

Duration of the research: The first patient will be included from 2023. The inclusion period is 18 months. Patients will be monitored for 6 months (+/- 2 months) after inclusion Healthy volunteers will have one visit (estimated time: 2H) The total duration of the clinical study is expected to be 26 months

Data analysis: The characteristics of the subjects as well as the various clinical indicators of swallowing and their evolution during monitoring will be described. Development and validation algorithms to model the various pharyngo-laryngeal effectiveness indicators and predictive algorithms of swallowing disorders will be produced using statistical approaches and also using machine learning. The signals obtained from the 5 sensors will be annotated. The signals will be standardized and synchronized to allow the modelling of the sequences corresponding to the following events: swallowing of food, saliva, cough, throat clearing, speech, wet voice. Stochastic modelling based on hidden Markov models will be used initially and followed by the implementation of deep neural networks to model indicators. For the complication's prediction algorithm, deep neural networks will also be used to evaluate signal-based methods.

Being tested
Swallowing evaluation
Medical subject headings
Deglutition Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Swallowing evaluationOther

    For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.

    For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)

Study groups in NCT06014710
Study groupRoleWhat they receive
Experimental armExperimentalPatients with swallowing disorders and healthy volunteers
Receives: Other: Swallowing evaluation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Swallowing efficacy

    Swallowing efficacy : pharyngeal transport capacity (assessed by the Yale Pharyngeal residue severity rating scale). The Yale Pharyngeal residue severity rating scale (YPRSRS) is a 5-point scale ranging from I (none) to V (severe).

    Measured: Baseline

  2. Swallowing safety

    Swallowing Safety : the Penetration Aspiration Scale (PAS) rated by VFS (videofluoroscopy of swallowing) or FEES (flexible endoscopic evaluation of swallowing). The Penetration Aspiration Scale (PAS) is a 8-point scale ranging from 1 to 8 : 1 is considered the best and 8 the worst

    Measured: Baseline

  3. Lung defense reflex

    Cough trigger reviewed by citric acid test

    Measured: Baseline

  4. Power of cough

    Cough power rated by peak expiratory flow in litres per minute

    Measured: Baseline

  5. Voice efficiency

    Vocal efficiency evaluated by maximum phonation time on the letter "a" held in seconds

    Measured: Baseline

  6. Velar efficiency

    velar efficiency evaluated by assessment of the sentences without nasal phonemes and sentences with nasal phonemes

    Measured: Baseline

Secondary outcomes (4)
  1. Self-assessment of severity of swallowing disorders

    Severity of swallowing disorders measured by patient self-assessment with visual analogic scale ranging from 1 = no severity to 10 = very severe.

    Measured: Baseline

  2. Severity of swallowing disorders assessed by oropharyngeal swallowing effectiveness scale

    Severity of swallowing disorders measured by oropharyngeal swallowing effectiveness scale from baseline studies (FEES or VFS). The OroPharyngeal Swallowing Efficiency (OPSE) is a subjective evaluation of the severity expressed as a percentage of the bolus actually passing through the esophagus according to the formula:

    100% (of the bolus introduced into the mouth) - X% of the bolus having gone astray - Y% of the bolus stagnating in the form of residue

    Measured: Baseline

  3. General quality of life assessment

    Quality of life assessed by euroqol 5-dimension 5-level questionnaire (EQ-5D-5L). The EQ-5D-5L is questionnaire with 5 items from 1 to 5 : 1 is considered the best and 5 the worst and a scale from 100 " the best health you can imagine " to 0 " the worst health you can imagine ".

    Measured: Baseline and 6 months

  4. Quality of life assessment for patients with cancer

    Quality of life assessed by Cancer Quality of life questionnaire (CLQ-C30) for patients with cancer. The CLQ-C30 questionnaire is composed of 30 items.

    Measured: Baseline and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2023
  2. Study start14 Apr 2023
  3. Primary completionApr 2027 (estimated)
  4. Study completionOct 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
520 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06014710
Sponsor's protocol ID
RC31/22/0091
Other IDs
2023-A00054-41
Acronym
Eph-L
Status last verified
Aug 2026
First submitted
11 Apr 2023
Last updated
13 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Swallowing evaluation in people with Swallowing Disorders, run by University Hospital, Toulouse at 4 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 29 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Virginie WOISARD, MD (33-567771718, woisard.v@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Swallowing efficacy (time frame: Baseline). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in